Search results for " glucocorticoid"

showing 10 items of 62 documents

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency

2019

Background Dual-release hydrocortisone (DR-HC) improves metabolism in patients with adrenal insufficiency. The aims of this study were to compare the cardiovascular and metabolic effects of conventional glucocorticoids (GCs) vs. DR-HC and of high vs. low doses of GCs, after 48 months of observation. Methods We selected 27 patients on hydrocortisone (mean dose 17.5 ± 4.2 mg/day) and 20 patients on cortisone acetate (mean dose 37.5 ± 12.1 mg/day) who maintained this treatment (group A) and 53 patients switched to DR-HC (mean dose 22 ± 4.8 mg/day) (group B). At baseline and after 48 months, clinical and metabolic parameters and Framingham Risk Score (FRS) were obtained. Results After 48 month…

medicine.medical_specialtyDiabetes mellituWaistDual releaseEndocrinology Diabetes and MetabolismUrology030209 endocrinology & metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyConventional glucocorticoidGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicineAdrenal insufficiencymedicineHydrocortisonelcsh:RC648-665Framingham Risk Scorebusiness.industryResearchconventional glucocorticoidsmedicine.diseaseCardiovascular riskBlood pressure030220 oncology & carcinogenesisdiabetes mellitusDual-release hydrocortisonebusinessAdrenal insufficiencymedicine.drug
researchProduct

Diabetes mellitus secondary to Cushing's disease

2018

Associated with important comorbidities that significantly reduce patients’ overall wellbeing and life expectancy, Cushing’s disease (CD) is the most common cause of endogenous hypercortisolism. Glucocorticoid excess can lead to diabetes, and although its prevalence is probably underestimated, up to 50% of patients with CD have varying degrees of altered glucose metabolism. Fasting glycemia may nevertheless be normal in some patients in whom glucocorticoid excess leads primarily to higher postprandial glucose levels. An oral glucose tolerance test should thus be performed in all CD patients to identify glucose metabolism abnormalities. Since diabetes mellitus (DM) is a consequence of cortis…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologyCarbohydrate metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineInsulin resistanceCortisol-lowering medication; Cushing's disease; Diabetes; Glucocorticoids; Insulin resistance; Endocrinology Diabetes and MetabolismEndocrinologyInternal medicineDiabetes mellitusmedicineGlucocorticoidslcsh:RC648-665business.industryDiabetesInsulin resistanceCushing's diseaseCushing’s diseasemedicine.diseaseDiabetes and MetabolismEndocrinologyPostprandialCortisol-lowering medicationCushing's diseasePituitary surgerybusinessGlucocorticoidmedicine.drug
researchProduct

Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

2020

Context: Glucocorticoid (GC) replacement therapy in patients with adrenal insufficiency (AI) is life saving. After over 50 years of conventional GC treatment, novel formulations are now entering routine clinical practice. Methods: Given the spectrum of medications currently available and new insights into the understanding of AI, the authors reviewed relevant medical literature with emphasis on original studies, prospective observational data and randomized controlled trials performed in the past 35 years. The Expert Opinion of a panel of selected endocrinologists was sought to answer specific clinical questions. The objective was to provide an evidence-supported guide, for the use of GC in…

medicine.medical_specialtyHydrocortisoneHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismlaw.inventionSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyGlucocorticoidRandomized controlled triallawPrednisonemedicineAdrenal insufficiencyOutpatient clinicHumansDosingIntensive care medicineGlucocorticoidsbusiness.industryAddison; Adrenal insufficiency; Cortisone acetate; Glucocorticoid; Hydrocortisone; Prednisonemedicine.diseaseItalyTransgender hormone therapyCortisone acetate030220 oncology & carcinogenesisPrednisoneObservational studybusinessMedical literaturemedicine.drugAddisonAdrenal InsufficiencyJournal of endocrinological investigation
researchProduct

Differential expression of two glucocorticoid receptors in seabass (teleost fish) head kidney after exogeneous cortisol inoculation

2009

Stressful conditions include a prompt release of corticosteroid hormones which can mediate gene expression through glucocorticoid receptors (GR). Since two seabass (Dicentrarchus labrax) GRs have been cloned and sequenced from peritoneal cavity cells (DlGR1) and liver (DlGR2), a comparative amino acid sequence analysis that included Haplochromis burtoni HbGRs, was carried out and homologies disclosed. The DlGR1 and DlGR2 deduced aminoacid sequences showed 61% identity (I) and 70% similarity (S). Moreover, DlGR2 was similar to HbGR2b (69% I, 73% S), and the DlGR1 to HbGR1 (72% I, 78% S). In addition, we examined the expression of the DlGRs after exogeneous cortisol inoculation into the perit…

medicine.medical_specialtyHydrocortisonePhysiologySettore BIO/05 - ZoologiaGlucocorticoid receptorKidneyBiochemistryCortisolPeritoneal cavityGlucocorticoid receptorReceptors GlucocorticoidInternal medicineGene expressionmedicineAnimalsDicentrarchus labraxSea bassMolecular BiologyDicentrarchus labrax; Cortisol; Glucocorticoid receptor; Real-time PCRHead KidneyKidneybiologyReverse Transcriptase Polymerase Chain ReactionGene Expression Profilingbiology.organism_classificationmedicine.anatomical_structureEndocrinologyGene Expression RegulationHormone receptorDicentrarchusBassReal-time PCR
researchProduct

Phosphodiesterase-4 inhibition improves corticosteroid insensitivity in pulmonary endothelial cells under oxidative stress.

2012

Several clinical studies have shown that smoking in asthmatics and chronic obstructive pulmonary disease patients is closely associated with corticosteroid refractoriness. In this work, we have analyzed glucocorticoid insensitivity in human pulmonary artery endothelial cells (HPAECs) under cigarette smoke extract (CSE) exposure as well as the possible additive effects of the combination therapy with a phosphodiesterase (PDE)-4 inhibitor. Interleukin (IL)-8 was measured in cell supernatants by ELISA. Histone deacetylase (HDAC), histone acetylase (HAT), and intracellular cAMP levels were measured by colorimetric assays and enzyme immunoassay, respectively. PDE4 isotypes and glucocorticoid rec…

medicine.medical_specialtyImmunologyApoptosisDexamethasoneHistone DeacetylasesGlucocorticoid receptorReceptors GlucocorticoidAdrenal Cortex HormonesInternal medicinemedicineCyclic AMPImmunology and AllergyHumansReceptorLungDexamethasoneRolipramCell ProliferationHistone AcetyltransferasesChemistryTumor Necrosis Factor-alphaInterleukin-8InterleukinPhosphodiesteraseEndothelial CellsAparato respiratorioCyclic Nucleotide Phosphodiesterases Type 4Enzyme ActivationOxidative StressEndocrinologyHistone deacetylasePhosphodiesterase 4 InhibitorsPulmonesReactive Oxygen SpeciesRolipramGlucocorticoidmedicine.drugAllergy
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia.

2019

Objective Subcutaneous fat necrosis (SCFN) is a rare condition that may occur in the neonatal period. SCFN is an inflammatory disorder of the adipose tissue, usually found in full-term healthy infants who have a history of intrauterine or perinatal distress. It is usually a self-limited condition; however, in some cases, it can get complicated, leading to severe hypercalcemia that may be life-threatening. Study Design We report and describe a classic presentation of SCFN that led to severe hypercalcemia refractory to standard treatment. The diagnosis of SCFN was made based on the finding of subcutaneous nodules and of hypercalcemia. The serum calcium level reached 16.6 mg/dL. Hypercalcemia…

medicine.medical_specialtyNecrosisTerm BirthDrug ResistanceSubcutaneous FatAdipose tissuehypercalcemia; neonate; subcutaneous fat necrosis; zoledronic acid; Bone Density Conservation Agents; Calcium; Drug Resistance; Fat Necrosis; Female; Furosemide; Glucocorticoids; Humans; Hypercalcemia; Infant Newborn; Methylprednisolone; Sodium Potassium Chloride Symporter Inhibitors; Subcutaneous Fat; Term Birth; Zoledronic AcidGastroenterologyMethylprednisoloneZoledronic AcidRefractorySodium Potassium Chloride Symporter InhibitorsFurosemideInternal medicinesubcutaneous fat necrosismedicineHumansFat necrosisFat NecrosisGlucocorticoidsBone Density Conservation Agentsbusiness.industryStandard treatmentInfant NewbornObstetrics and GynecologyFurosemideInfantmedicine.diseaseNewbornZoledronic acidMethylprednisolonePediatrics Perinatology and Child HealthHypercalcemiaCalciumFemalemedicine.symptomneonatebusinessmedicine.drugAmerican journal of perinatology
researchProduct

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

2015

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mech anisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient's quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients. In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations …

medicine.medical_specialtyPediatricsCyclosporine; Eyelid surgery; Glucocorticoids; Graves' orbitopathy; Orbital decompression; Orbital radiotherapy; Rituximab; Selenium; Squint surgeryEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedizin030209 endocrinology & metabolismDiseaseGuidelines03 medical and health sciencesGraves' orbitopathySeleniumEndocrinology0302 clinical medicineQuality of lifemedicineEyelid surgeryOrbital radiotherapyGlucocorticoidsbusiness.industryCumulative doseThyroideye diseasesSurgeryDiabetes and MetabolismOrbital decompressionArtificial tearsmedicine.anatomical_structureMethylprednisolone030221 ophthalmology & optometryCyclosporineRituximabSquint surgerybusinessRituximabWatchful waitingCyclosporine; Eyelid surgery; Glucocorticoids; Graves' orbitopathy; Orbital decompression; Orbital radiotherapy; Rituximab; Selenium; Squint surgery; Endocrinology Diabetes and Metabolismmedicine.drug
researchProduct

Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma

2004

Background In asthma T cells are characterized by an increased activation state and by reduced apoptosis. Objective Because the clinical efficacy of inhaled corticosteroids combined with long-acting β 2 -agonists has been widely demonstrated in asthma, we studied, in vitro , the effect of fluticasone propionate (FP) and salmeterol alone and in combination on the activation and apoptosis of peripheral blood T cells (PBTs), on the expression of phosphorylated nuclear factor κB inhibitor (IκBα), and on the nuclear translocation of glucocorticoid receptor (GR) in PBTs from asthmatic subjects. Methods Apoptosis was evaluated on the basis of annexin V binding, whereas the expression of caspases 8…

medicine.medical_specialtyProgrammed cell deathAdolescentT cellT-LymphocytesImmunologyActive Transport Cell NucleusApoptosisAndrostadienes; Active Transport Cell Nucleus; NF-kappa B; Apoptosis; Humans; Albuterol; Receptors Glucocorticoid; Asthma; Child; Caspases; Lymphocyte Activation; Phosphorylation; I-kappa B Proteins; Adolescent; Drug Synergism; T-LymphocytesLymphocyte ActivationGlucocorticoid receptorReceptors GlucocorticoidNF-KappaB Inhibitor alphaAnnexinInternal medicinemedicineHumansImmunology and AllergyAlbuterolPhosphorylationChildSalmeterol XinafoateAndrostadieneChemistryActive Transport Cell NucleuNF-kappa BApoptosiDrug SynergismCaspaseAsthmaAndrostadienesIκBαEndocrinologymedicine.anatomical_structureApoptosisCaspasesFluticasoneI-kappa B ProteinI-kappa B ProteinsSalmeterolGlucocorticoidmedicine.drugHuman
researchProduct

Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis.

2018

Objective: To characterize the etiologies and clinical features at diagnosis of patients with hemophagocytic lymphohistiocytosis (HLH) and correlate these baseline features with survival using an etiopathogenically guided multivariable model. Patients and Methods: The Spanish Group of Autoimmune Diseases HLH Study Group, formed in 2013, is aimed at collecting adult patients with HLH diagnosed in internal medicine departments between January 3, 2013, and October 28, 2017. Results: The cohort consisted of 151 patients (91 men; mean age, 51.4 years). After a mean follow-up of 17 months (range, 1-142 months), 80 patients died. Time-to-event analyses for death identified a worse survival curve f…

medicine.medical_specialtymedicine.medical_treatmentHLH hemophagocytic lymphohistiocytosislaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineGC glucocorticoidEpidemiologymedicine030212 general & internal medicineSurvival analysislcsh:R5-920Hemophagocytic lymphohistiocytosisID immunosuppressive drugbusiness.industryMortality ratemedicine.diseaseICU intensive care unitIntensive care unitIVIG intravenous immunoglobulinImmunosuppressive drug030220 oncology & carcinogenesisCohortEtiologylcsh:Medicine (General)businessNK natural killerMayo Clinic proceedings. Innovations, qualityoutcomes
researchProduct